Caris Life Sciences, Inc. Common Stock (CAI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Caris Life Sciences, Inc. Common Stock.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 15.70 $ — 5% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
9 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 46.5% passed
- More than 10% revenue growth is expected for the coming year 19.9% passed
- Share count grows by less than 3% a year 87.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 105.2% passed
- Gross margin at 40% or higher and without meaningful erosion 66.4% passed
- Goodwill from acquisitions does not grow faster than revenue 1.7% passed
- Net debt below twice EBITDA 421 m net cash passed
- Operating cash flow covers the profits of the last three years 723 m passed
- Return on capital at 15% or higher, or up versus two years ago 4.5% passed
- Insiders hold at least 10% or are net buyers 48.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 77.3% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | – | – | – | – | – | – | – |
| 2025: Q1 | -0.40 | -113.80 | 121 | 19.90 | -84.80 | -31 | -34 |
| 2025: Q2 | -0.26 | – | 181 | 124.80 | -39.60 | 7 | 6 |
| 2025: Q3 | 0.08 | – | 217 | 116.70 | 11.20 | 62 | 55 |
| 2025: Q4 | 0.05 | – | 293 | – | 28.00 | 45 | 40 |
| 2026: Q1 | 0.00 | – | 216 | 78.80 | -0.20 | 33 | 23 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Caris Life Sciences, Inc., ein KI-TechBio-Unternehmen, bietet molekulare Profiling-Dienste in den USA und international an.
| Employees | 1,846 |
|---|---|
| Headquarters | Irving, TX |
| Website | carislifesciences.com |
| IPO Date | 18. Jun 2025 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David Dean Halbert M.D. | Chairman, CEO & Founder | 1956 |
| Brian J. Brille J.D. | Executive Vice Chairman & Executive VP | 1962 |
| David Spetzler M.B.A., M.S., Ph.D. | President | 1977 |
| J. Russel Denton | Senior VP, General Counsel & Secretary | 1984 |
| Luke Power | Senior VP, CFO & Chief Accounting Officer | 1982 |
| Jon Mark Harmon | Senior VP & Chief Operations Officer | – |
| Valeriy Domenyuk | Senior VP & CTO | – |
| Milan Radovich Ph.D. | Senior VP & Chief Scientific Officer | – |
| Narendra Chokshi | Senior Vice President of Corporate Development | – |
| Jeremy O'Brien | Senior Vice President of Human Resources | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. May 2026 | Halbert Jon | Director | Buy | 68,000 | 14.56 | 990,080 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.